This federal contract award, identified as SPE2DB24D8002|SPE2DB24FJNAG, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The $17,696.27 firm fixed-price contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a prescription medication. This award is a delivery order under Dakota Drug, Inc.'s existing Indefinite Delivery Contract (IDC) SPE2DB24D8001 with the DLA Troop Support Medical's ECAT Generation V Program, which has a total potential value of $999,999,999.00 and runs through December 31, 2025. The contract does not have a set-aside designation. Through this and other high-value DLA contracts, Dakota Drug, Inc. plays a crucial role in supporting the medical supply chain operations for the U.S. Armed Forces.
Generated 12/25/24, 9:11 AM